Early delivery and prolonged treatment with nimodipine prevents the development of spasticity after spinal cord injury in mice.
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
15 04 2020
15 04 2020
Historique:
received:
13
05
2019
revised:
17
12
2019
accepted:
28
02
2020
entrez:
17
4
2020
pubmed:
17
4
2020
medline:
1
6
2021
Statut:
ppublish
Résumé
Spasticity, one of the most frequent comorbidities of spinal cord injury (SCI), disrupts motor recovery and quality of life. Despite major progress in neurorehabilitative and pharmacological approaches, therapeutic strategies for treating spasticity are lacking. Here, we show in a mouse model of chronic SCI that treatment with nimodipine-an L-type calcium channel blocker already approved from the European Medicine Agency and from the U.S. Food and Drug Administration-starting in the acute phase of SCI completely prevents the development of spasticity measured as increased muscle tone and spontaneous spasms. The aberrant muscle activities associated with spasticity remain inhibited even after termination of the treatment. Constitutive and conditional silencing of the L-type calcium channel Ca
Identifiants
pubmed: 32295897
pii: 12/539/eaay0167
doi: 10.1126/scitranslmed.aay0167
pii:
doi:
Substances chimiques
Calcium Channel Blockers
0
Calcium Channels, L-Type
0
Nimodipine
57WA9QZ5WH
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.